Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 08 Dec 2022
Takeda’s Qdenga (dengue tetravalent vaccine [live, attenuated]) approved for use in European Union
8 December 2022 - Qdenga becomes the only dengue vaccine approved in the EU for use in individuals regardless of previous ...
Posted by Michael Wonder on 08 Dec 2022
Speedier drug approvals hit slowdown as FDA faces scrutiny
7 December 2022 - Expedited drug approvals slowed this year as the FDA’s controversial accelerated pathway came under new scrutiny ...
Posted by Michael Wonder on 08 Dec 2022
IQWiG updates its General Methods
6 December 2022 - Revision of the cost-benefit assessment and addition of the concept of application-accompanying data collection: Comments on ...
Posted by Michael Wonder on 08 Dec 2022
NICE recommends Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus refractory (with or without resistance) to prior therapies
8 December 2022 - Livtencity is the first and only oral treatment that inhibits CMV specific UL97 protein kinase and ...
Posted by Michael Wonder on 08 Dec 2022
Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
8 December 2022 - The decision by the Italian AIFA provides highly sensitised patients in Italy with the opportunity to ...
Posted by Michael Wonder on 08 Dec 2022
Visiox Pharma announces FDA acceptance of new drug application for glaucoma
8 December 2022 - Visiox Pharma today announced that it has received notification from the US FDA that the agency ...
Posted by Michael Wonder on 08 Dec 2022
Osteoporosis after menopause: fewer vertebral fractures with teriparatide than with risedronate
5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab ...
Posted by Michael Wonder on 07 Dec 2022
US backs delay to decision on COVID patent waiver extension
6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...
Posted by Michael Wonder on 07 Dec 2022
Updated eligibility for COVID-19 oral treatment
7 December 2022 - COVID-19 treatments can be taken in your own home and can help reduce your symptoms. ...
Posted by Michael Wonder on 07 Dec 2022
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
7 December 2022 - Novavax today announced that Health Canada has approved a supplement to a new drug submission for Nuvaxovid ...
Posted by Michael Wonder on 07 Dec 2022
Moleculin granted FDA fast track designation of WP1122 for the treatment of glioblastoma multiforme
7 December 2022 - Moleculin Biotech today announced that the US FDA has granted fast track designation of WP1122 for the ...
Posted by Michael Wonder on 07 Dec 2022
US FDA accepts for priority review the biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate for the prevention of RSV disease in older adults
7 December 2022 - If approved, RSVpreF would help address the substantial burden of RSV disease in individuals 60 years ...
Posted by Michael Wonder on 07 Dec 2022
PHARMAC funds more medicines for New Zealanders
8 December 2022 - PHARMAC has today announced decisions to fund two new medicines and widen access to one other. ...
Posted by Michael Wonder on 07 Dec 2022
Tukysa (tucatinib) reimbursed in British Columbia for the treatment of patients with advanced or metastatic HER2 positive breast cancer
6 December 2022 - BC is the third province to add Tukysa to its provincial dormulary. ...
Posted by Michael Wonder on 07 Dec 2022
Migraine Foundation submits application to PHARMAC to fund Emgality
5 December 2022 - Migraine Foundation Aotearoa New Zealand has submitted a consumer application to Pharmac to fund Emgality (galcanezumab) for ...